Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
ECOR vs EQ: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
EQ Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–2 Matrix Metrics)
EQ Overall Winner
6-Pillar Tally: ECOR 2 – 3 EQ (1 Tie)
Matrix Metrics: ECOR 2 – 8 EQ
As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over electroCore, Inc. (ECOR) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). ECOR carries a Unified Composite Score of 56.8/100 (HOLD) at $4.85 (N/M Forward P/E, -33.1% operating margin), whereas EQ carries 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While ECOR currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. EQ 48.0/100 HOLD), EQ captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -33.1% operating margin) and revenue trajectory (-52.3% vs. +11.5% YoY).
- Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ECOR vs EQ
ECOR
electroCore, Inc. Common Stock
$4.85
-6.19% 1D
Market Cap
$47.7M
TTM Revenue
$38M
Forward P/E
N/M
Beta / 30D Vol
1.52β · 155% Vol
Unified Composite Score
56.8
HOLD
Tech 68.0
Fund 53.0
Flow 50.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
EQ
Head-to-Head Winner
Equillium, Inc. Common Stock
$1.12
+1.82% 1D
Market Cap
$90.6M
TTM Revenue
$4.4M
Forward P/E
1.5x
Beta / 30D Vol
1.53β · 93% Vol
Unified Composite Score
48.0
HOLD
Tech 30.0
Fund 51.0
Flow 63.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (ECOR 2 – 3 EQ)
1. Valuation Multiples
EQ
Forward P/E
N/M
1.5x
Trailing P/E
N/M
1.5x
PEG Ratio
N/M
N/M
EV / Revenue
1.4x
7.7x
2. Growth & Scale
ECOR
Revenue Growth (YoY)
+11.5%
-52.3%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$38M
$4.4M
Market Cap
$47.7M
$90.6M
3. Profitability & Quality
EQ
Gross Margin
87.7%
100.0%
Operating Margin
-33.1%
0.0%
Net Profit Margin
-33.5%
0.0%
Return on Equity (ROE)
-478.7%
-59.0%
4. Balance Sheet & Cash Flow
ECOR
Cash Generation (TTM)
-$6.9M
-$20M
Cash Flow Margin
-18.1%
N/A
Net Cash / Leverage
$4.6M Net Debt
$57M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
EQ
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
261.3% (100th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ECOR (2) vs EQ (8)| Institutional Metric | ECOR | EQ | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $47.7M | $90.6M | EQ | |
| Trailing P/E Ratio | N/M | 1.5x | EQ | |
| Forward P/E Ratio | N/M | 1.5x | EQ | |
| Revenue Growth (YoY) | +11.5% | -52.3% | ECOR | |
| Operating Margin (TTM) | -33.1% | 0.0% | EQ | |
| Net Profit Margin | -33.5% | 0.0% | EQ | |
| Return on Equity (ROE) | -478.7% | -59.0% | EQ | |
| 52-Week Range Position | 6% ($4–$13) | 11% ($1–$4) | EQ | |
| Beta / 30D Volatility | 1.52β · 155% Vol | 1.53β · 93% Vol | EQ | |
| Unified Institutional Score | 56.8 / 100 (HOLD) | 48.0 / 100 (HOLD) | ECOR | |
| Trailing 12M Revenue (USD) | $38M | $4.4M | Scale | |
| Gross Profit Margin (TTM) | 87.7% | 100.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 1.4x EV/Rev | N/M PEG · 7.7x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$6.9M ($4.6M Net Debt) | -$20M ($57M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
EQ +12.88 pp
3M Horizon
EQ +2.38 pp
6M Horizon
ECOR +30.29 pp
1Y Horizon
EQ +15.96 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ECOR Revenue | EQ Revenue | ECOR Op. Margin | EQ Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -5494.1% | N/A | ECOR |
| FY2019 | $0M | N/A | -1928.2% | N/A | ECOR |
| FY2020 | $0M | N/A | -707.9% | N/A | ECOR |
| FY2021 | $10M | N/A | -367.7% | N/A | ECOR |
| FY2022 | $10M | $20M | -266.2% | -393.9% | ECOR |
| FY2023 | $20M | $40M | -120.2% | -40.2% | EQ |
| FY2024 | $30M | $40M | -48.3% | -20.1% | EQ |
| FY2025 | $30M | N/A | -41.1% | N/A | ECOR |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ECOR
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ECOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
EQ
UNCLASSIFIED
Current IV
261.3%
IV Percentile
100th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact EQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ECOR Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
EQ Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ECOR vs EQ Key Questions & Quantitative Answers
As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over electroCore, Inc. (ECOR) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). ECOR carries a Unified Composite Score of 56.8/100 (HOLD) at $4.85 (N/M Forward P/E, -33.1% operating margin), whereas EQ carries 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ECOR currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. EQ 48.0/100 HOLD), EQ captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -33.1% operating margin) and revenue trajectory (-52.3% vs. +11.5% YoY). Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ECOR leads the Growth & Scale pillar: ECOR posts +11.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (87.7% gross margin, -33.1% operating margin), compared with EQ at -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ECOR cumulative revenue shifted +200.0% while EQ shifted +100.0%. In operating R&D and SG&A reinvestment, ECOR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EQ.
EQ screens cheaper on headline valuation multiples. ECOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.4x EV/Revenue (-18.1% FCF margin), whereas EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 7.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ECOR (-478.7% ROE) versus EQ (-59.0% ROE) capital efficiency.
In options market volatility and institutional positioning, ECOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 155% Vol realized risk). By comparison, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.53β · 93% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
EQ vs ECOR · Reverse Pair
ECOR vs PRPO
· Sector Peer
EQ vs CRVS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal